

Need By Date: _____ Ship To: ☐ Patient ☐ Office ☐ Other _____ Fax Copy: ☐ Rx Card Front/Back ☐ Clinical Notes ☐ Medical Card Front/Back

Patient Information		Prescriber Information	
Patient Name		Prescriber Name	
Address		Address	
City State ZIP		City State ZIP	
Main Phone	Alternate Phone	Phone	Fax
Social Security #		Contact Person	
Date of Birth	<input type="checkbox"/> Female <input type="checkbox"/> Male	DEA #	NPI # License #

Clinical Information	
Diagnosis: <input type="checkbox"/> L20.9 Atopic Dermatitis <input type="checkbox"/> L40.0 Moderate to Severe Plaque Psoriasis <input type="checkbox"/> L40.50 Psoriatic Arthritis <input type="checkbox"/> L73.2 Hidradenitis Suppurativa - Hurley Stage: _____ <input type="checkbox"/> Other: _____ Dx Code: _____	
Location: Joints: <input type="checkbox"/> Hands <input type="checkbox"/> Feet <input type="checkbox"/> Knees <input type="checkbox"/> Spine Skin: <input type="checkbox"/> Hands <input type="checkbox"/> Feet <input type="checkbox"/> Scalp <input type="checkbox"/> Groin <input type="checkbox"/> Nails <input type="checkbox"/> Other: _____ % BSA: _____	
Prior Failed Meds: <input type="checkbox"/> Biologics: _____ <input type="checkbox"/> Oral: _____ <input type="checkbox"/> Topical: _____ <input type="checkbox"/> Other: _____	
Drug Allergies	Latex Allergy: <input type="checkbox"/> No <input type="checkbox"/> Yes
Weight <input type="checkbox"/> kg <input type="checkbox"/> lbs	TB Test: <input type="checkbox"/> No <input type="checkbox"/> Yes Date: _____ Results: <input type="checkbox"/> Negative <input type="checkbox"/> Positive (please send lab results) Status: <input type="checkbox"/> New <input type="checkbox"/> Restart <input type="checkbox"/> Continuing

Prescription Information			Qty	Refills
<input type="checkbox"/> Adbry® *12+ Years Old	150 mg PFS	<input type="checkbox"/> Load: Inject 300 mg (as two-150 mg injections) SUBQ on Day 1, then inject 150 mg SUBQ every other week starting on Day 15 <input type="checkbox"/> Maintenance: Inject 150 mg SUBQ every other week starting on Day 15	2 Syringes 2 Syringes	None _____
<input type="checkbox"/> Cibinqo™ *12+ Years Old	<input type="checkbox"/> 50 mg <input type="checkbox"/> 100 mg <input type="checkbox"/> 200 mg	<input type="checkbox"/> Take 1 tablet by mouth once daily	30 Tablets	_____
<input type="checkbox"/> Cosentyx®	<input type="checkbox"/> 75 mg PFS 150 mg <input type="checkbox"/> Pen <input type="checkbox"/> PFS	<input type="checkbox"/> Load: Inject 75 mg SUBQ on week 0, 1, 2, 3 (<50 kg) <input type="checkbox"/> Maintenance: Inject 75 mg SUBQ on week 4, then every 4 weeks thereafter (<50 kg) <input type="checkbox"/> Load: Inject 150 mg SUBQ on week 0, 1, 2, 3 (≥50 kg) <input type="checkbox"/> Maintenance: Inject 150 mg SUBQ on week 4, then every 4 weeks thereafter (≥50 kg)	4 Week Supply 4 Week Supply 4 Week Supply 4 Week Supply	None _____ None _____
<input type="checkbox"/> Dupixent® *Age 6 Months-5 Years Old	<input type="checkbox"/> 200 mg PFS w/Shield <input type="checkbox"/> 200 mg Pen (2+ years old) <input type="checkbox"/> 300 mg PFS w/Shield <input type="checkbox"/> 300 mg Pen (2+ years old)	<input type="checkbox"/> Inject 200 mg SUBQ every 4 weeks (5 kg to <15 kg) <input type="checkbox"/> Inject 300 mg SUBQ every 4 weeks (15 kg to <30 kg)	2 Syringes 2 Syringes	_____ _____
<input type="checkbox"/> Dupixent® *Age 6-17 Years Old	<input type="checkbox"/> 300 mg PFS w/Shield <input type="checkbox"/> 300 mg Pen <input type="checkbox"/> 200 mg PFS w/Shield <input type="checkbox"/> 200 mg Pen <input type="checkbox"/> 300 mg PFS w/Shield <input type="checkbox"/> 300 mg Pen	<input type="checkbox"/> Load: Inject 600 mg (as two-300 mg injections in different sites) on Day 1, then 300 mg every 4 weeks starting on Day 29 (15kg to <30kg) <input type="checkbox"/> Maintenance: Inject 300 mg SUBQ once every 4 weeks starting on Day 29 (15 kg to <30 kg) <input type="checkbox"/> Load: Inject 400 mg (as two-200 mg injections in different sites) on Day 1, then 200 mg every other week starting on Day 15 (30 kg to <60 kg) <input type="checkbox"/> Maintenance: Inject 200 mg SUBQ once every other week starting on Day 15 (30 kg to <60 kg) <input type="checkbox"/> Load: Inject 600 mg (as two-300 mg injections in different sites) on Day 1, then 300 mg every other week starting on Day 15 (≥60 kg) <input type="checkbox"/> Maintenance: Inject 300 mg SUBQ every other week starting on Day 15 (≥60 kg)	2 Syringes 2 Syringes 2 Syringes 2 Syringes 2 Syringes 2 Syringes	None _____ None _____ None _____
<input type="checkbox"/> Ebglyss™ *12+ Years Old: ≥40 kg	<input type="checkbox"/> 250 mg Pen <input type="checkbox"/> 250 mg PFS	<input type="checkbox"/> Initial: Inject 500 mg (as two-250 mg injections) SUBQ at week 0 and week 2 <input type="checkbox"/> Induction: Inject 250 mg SUBQ every 2 weeks (weeks 4-14). If additional induction dosing is needed, contact the pharmacy. <input type="checkbox"/> Maintenance: Inject 250 mg SUBQ every 4 weeks, starting week 16.	4 Injections 2 Injections 1 Injection	None 2 _____
<input type="checkbox"/> Enbrel®	50 mg <input type="checkbox"/> SureClick® <input type="checkbox"/> PFS <input type="checkbox"/> Mini <input type="checkbox"/> 25 mg PFS <input type="checkbox"/> 25 mg/0.5 mL SDV	<input type="checkbox"/> Inject 50 mg SUBQ once a week (≥63 kg) <input type="checkbox"/> Inject 25 mg SUBQ once a week <input type="checkbox"/> Inject _____ mg (0.8 mg/kg) subcutaneously once a week (<63 kg)	4 Week Supply 4 Week Supply 4 Week Supply	_____ _____ _____
<input type="checkbox"/> Other				

By signing this form, you are authorizing BioPlus Specialty Pharmacy and its employees to serve as your designated agent in submitting clinical and other required information to third party payers with respect to this prescription and any refills or continuation of the same medication and dose for this patient. IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

Prescriber's Signature (no stamps) Substitution Permitted

Date

Prescriber's Signature (no stamps) Dispense As Written

Date

BSP250625

Need By Date: _____ Ship To: ☐ Patient ☐ Office ☐ Other _____ Fax Copy: ☐ Rx Card Front/Back ☐ Clinical Notes ☐ Medical Card Front/Back

Patient Information		Prescriber Information		
Patient Name		Prescriber Name		
Address		Address		
City State ZIP		City State ZIP		
Main Phone	Alternate Phone	Phone	Fax	
Social Security #		Contact Person		
Date of Birth	<input type="checkbox"/> Female <input type="checkbox"/> Male	DEA #	NPI #	License #
Clinical Information				
Diagnosis: <input type="checkbox"/> L20.9 Atopic Dermatitis <input type="checkbox"/> L40.0 Moderate to Severe Plaque Psoriasis <input type="checkbox"/> L40.50 Psoriatic Arthritis <input type="checkbox"/> L73.2 Hidradenitis Suppurativa - Hurley Stage: _____ <input type="checkbox"/> Other: _____ Dx Code: _____				
Location: Joints: <input type="checkbox"/> Hands <input type="checkbox"/> Feet <input type="checkbox"/> Knees <input type="checkbox"/> Spine Skin: <input type="checkbox"/> Hands <input type="checkbox"/> Feet <input type="checkbox"/> Scalp <input type="checkbox"/> Groin <input type="checkbox"/> Nails <input type="checkbox"/> Other: _____ % BSA: _____				
Prior Failed Meds: <input type="checkbox"/> Biologics: _____ <input type="checkbox"/> Oral: _____ <input type="checkbox"/> Topical: _____ <input type="checkbox"/> Other: _____				
Drug Allergies				Latex Allergy: <input type="checkbox"/> No <input type="checkbox"/> Yes
Weight <input type="checkbox"/> kg <input type="checkbox"/> lbs	TB Test: <input type="checkbox"/> No <input type="checkbox"/> Yes Date: _____ Results: <input type="checkbox"/> Negative <input type="checkbox"/> Positive (please send lab results)		Status: <input type="checkbox"/> New <input type="checkbox"/> Restart <input type="checkbox"/> Continuing	

Prescription Information			Qty	Refills
<input type="checkbox"/> Humira® HS Citrate Free *Adol: 30 kg-59 kg	<input type="checkbox"/> PsO/UV Starter Pkg (Pens only) 40 mg <input type="checkbox"/> Pen <input type="checkbox"/> PFS	<input type="checkbox"/> Load: Inject 80 mg SUBQ on Day 1, then 40 mg on Day 8, then 40 mg every other week thereafter <input type="checkbox"/> Maintenance: Inject 40 mg SUBQ every other week	Loading Dose 4 Week Supply	None _____
<input type="checkbox"/> Humira® HS Citrate Free *Adol: ≥60 kg	<input type="checkbox"/> HS Starter Pkg (Pens only) 40 mg <input type="checkbox"/> Pen <input type="checkbox"/> PFS	<input type="checkbox"/> Load: Inject 160 mg SUBQ as <input type="checkbox"/> two-80 mg injections on Day 1 or <input type="checkbox"/> one-80 mg injection on Day 1 and then Day 2, then inject 80 mg on Day 15, then inject 40 mg every week thereafter starting on Day 29 <input type="checkbox"/> Maintenance: Inject 40 mg SUBQ every week	Loading Dose 4 Week Supply	None _____
<input type="checkbox"/> Humira® HS Citrate Free *HS Adol: ≥60 kg	<input type="checkbox"/> HS Starter Pkg (Pens only) <input type="checkbox"/> 80 mg Pen	<input type="checkbox"/> Load: Inject 160 mg SUBQ as <input type="checkbox"/> two-80 mg injections on Day 1 or <input type="checkbox"/> one-80 mg injection on Day 1 and then Day 2, then inject 80 mg on Day 15, then inject 80 mg every other week thereafter starting on Day 29 <input type="checkbox"/> Maintenance: Inject 80 mg SUBQ every other week	Loading Dose 4 Week Supply	None _____
<input type="checkbox"/> Litalo™ *12+ Years Old	50 mg Capsule	<input type="checkbox"/> Take 1 capsule by mouth once daily	28 Capsules	_____
<input type="checkbox"/> Nemluvio® *12+ Years Old	30 mg Pen	<input type="checkbox"/> Load: Inject 60 mg (as two-30 mg pens) SUBQ at week 0 <input type="checkbox"/> Maintenance: Inject 30 mg (1 pen) SUBQ every 4 weeks	2 Pens 1 Pen	None _____
<input type="checkbox"/> Otezla® *20 kg to <50 kg	<input type="checkbox"/> 10 mg-20 mg Starter Pack <input type="checkbox"/> 20 mg Tablet	<input type="checkbox"/> Take 1 tablet by mouth on Day 1 then twice daily as directed or date provided _____ <input type="checkbox"/> Take 1 tablet by mouth twice daily For Bridge Requests please utilize the Otezla Support Plus Start Form and fax to BioPlus Specialty Pharmacy at 800-269-5493	1 Starter Pack 60 Tablets	None _____
<input type="checkbox"/> Otezla® *≥50 kg	<input type="checkbox"/> 10 mg-20 mg-30 mg Starter Pack <input type="checkbox"/> 30 mg Tablet	<input type="checkbox"/> Take 1 tablet by mouth on Day 1 then twice daily as directed or date provided _____ <input type="checkbox"/> Take 1 tablet by mouth twice daily For Bridge Requests please utilize the Otezla Support Plus Start Form and fax to BioPlus Specialty Pharmacy at 800-269-5493	1 Starter Pack 60 Tablets	None _____
<input type="checkbox"/> Other				

By signing this form, you are authorizing BioPlus Specialty Pharmacy and its employees to serve as your designated agent in submitting clinical and other required information to third party payers with respect to this prescription and any refills or continuation of the same medication and dose for this patient. IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

Prescriber's Signature (no stamps) Substitution Permitted

Date

Prescriber's Signature (no stamps) Dispense As Written

Date

BSP250625

Need By Date: _____ Ship To: ☐ Patient ☐ Office ☐ Other _____ Fax Copy: ☐ Rx Card Front/Back ☐ Clinical Notes ☐ Medical Card Front/Back

Patient Information		Prescriber Information		
Patient Name		Prescriber Name		
Address		Address		
City State ZIP		City State ZIP		
Main Phone	Alternate Phone	Phone	Fax	
Social Security #		Contact Person		
Date of Birth	<input type="checkbox"/> Female <input type="checkbox"/> Male	DEA #	NPI #	License #

Clinical Information	
Diagnosis: <input type="checkbox"/> L20.9 Atopic Dermatitis <input type="checkbox"/> L40.0 Moderate to Severe Plaque Psoriasis <input type="checkbox"/> L40.50 Psoriatic Arthritis <input type="checkbox"/> L73.2 Hidradenitis Suppurativa - Hurley Stage: _____ <input type="checkbox"/> Other: _____ Dx Code: _____	
Location: Joints: <input type="checkbox"/> Hands <input type="checkbox"/> Feet <input type="checkbox"/> Knees <input type="checkbox"/> Spine Skin: <input type="checkbox"/> Hands <input type="checkbox"/> Feet <input type="checkbox"/> Scalp <input type="checkbox"/> Groin <input type="checkbox"/> Nails <input type="checkbox"/> Other: _____ % BSA: _____	
Prior Failed Meds: <input type="checkbox"/> Biologics: _____ <input type="checkbox"/> Oral: _____ <input type="checkbox"/> Topical: _____ <input type="checkbox"/> Other: _____	
Drug Allergies	Latex Allergy: <input type="checkbox"/> No <input type="checkbox"/> Yes
Weight <input type="checkbox"/> kg <input type="checkbox"/> lbs TB Test: <input type="checkbox"/> No <input type="checkbox"/> Yes Date: _____ Results: <input type="checkbox"/> Negative <input type="checkbox"/> Positive (please send lab results)	Status: <input type="checkbox"/> New <input type="checkbox"/> Restart <input type="checkbox"/> Continuing

Prescription Information			Qty	Refills
<input type="checkbox"/> Rinvoq® *12+ Years Old; ≥40 kg	<input type="checkbox"/> 15 mg ER Tablet <input type="checkbox"/> 30 mg ER Tablet	<input type="checkbox"/> Take 1 tablet by mouth once daily	30 Tablets	_____
<input type="checkbox"/> Stelara® Psoriasis	<input type="checkbox"/> 45 mg Vial (<60 kg)	<input type="checkbox"/> Starter: Inject _____ mg (0.75 mg/kg) SUBQ on week 0 <input type="checkbox"/> Maintenance: Inject _____ mg (0.75 mg/kg) SUBQ on week 4, then every 12 weeks thereafter	1 Vial 1 Vial	None _____
	<input type="checkbox"/> 45 mg PFS (60 kg to ≤100 kg) <input type="checkbox"/> 90 mg PFS (>100 kg)	<input type="checkbox"/> Starter: Inject 1 syringe SUBQ on week 0 <input type="checkbox"/> Maintenance: Inject 1 syringe SUBQ on week 4, and then every 12 weeks thereafter	1 Syringe 1 Syringe	None _____
<input type="checkbox"/> Stelara® Psoriatic Arthritis	<input type="checkbox"/> 45 mg Vial (<60 kg)	<input type="checkbox"/> Starter: Inject _____ mg (0.75 mg/kg) SUBQ on week 0 <input type="checkbox"/> Maintenance: Inject _____ mg (0.75 mg/kg) SUBQ on week 4, then every 12 weeks thereafter	1 Vial 1 Vial	None _____
	<input type="checkbox"/> 45 mg PFS (≥60 kg) <input type="checkbox"/> 90 mg PFS (>100 kg with Ps)	<input type="checkbox"/> Starter: Inject 1 syringe SUBQ on week 0 <input type="checkbox"/> Maintenance: Inject 1 syringe SUBQ on week 4, and then every 12 weeks thereafter	1 Syringe 1 Syringe	None _____
<input type="checkbox"/> Taltz®	<input type="checkbox"/> 40 mg PFS	<input type="checkbox"/> Starter: Inject 40 mg SUBQ on Day 1 (<25 kg)	1 Syringe	None
	<input type="checkbox"/> 20 mg PFS	<input type="checkbox"/> Maintenance: Inject 20 mg SUBQ every 4 weeks thereafter (<25 kg)	1 Syringe	_____
	<input type="checkbox"/> 80 mg PFS <input type="checkbox"/> 40 mg PFS	<input type="checkbox"/> Starter: Inject 80 mg SUBQ on Day 1 (25 kg to 50 kg) <input type="checkbox"/> Maintenance: Inject 40 mg SUBQ every 4 weeks thereafter (25 kg to 50 kg)	1 Syringe 1 Syringe	None _____
	80 mg <input type="checkbox"/> Pen <input type="checkbox"/> PFS	<input type="checkbox"/> Starter: Inject 160 mg (as two-80 mg injections) SUBQ on Day 1 (>50 kg) <input type="checkbox"/> Maintenance: Inject 80 mg SUBQ every 4 weeks thereafter (>50 kg)	2 Syringes 1 Syringe	None _____
<input type="checkbox"/> Other				

By signing this form, you are authorizing BioPlus Specialty Pharmacy and its employees to serve as your designated agent in submitting clinical and other required information to third party payers with respect to this prescription and any refills or continuation of the same medication and dose for this patient. IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

Prescriber's Signature (no stamps) Substitution Permitted

Date

Prescriber's Signature (no stamps) Dispense As Written

Date

BSP250625